Delivery Order SPE2DB24D1205-SPE2DB25FCYTL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,279.31 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price, competitively awarded contract without set-aside designation represents a single delivery order under AmerisourceBergen's larger federal pharmaceutical supply framework. The product will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 21, 2025, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a small-value pharmaceutical supply transaction. The award was placed of performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order valued at $22,851.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on July 18, 2025, with a completion date of July 21, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $13,364.72 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets in quantities of 30 units. This firm fixed price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order valued at $64,574.25 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) with an ultimate completion date of July 21, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a $3,619.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award supports the company's role as a prime pharmaceutical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for RINVOQ ER 15 mg tablets (30-count units) valued at $21,792.60. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. The...
- The Defense Logistics Agency awarded a $6,114.66 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract executed on July 21, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $15,876.35 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed price contract, with an ultimate completion date of July 21, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCYTLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $53,675.87 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count packages) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that serves as a global pharmaceutical support vehicle. The IDC enables the company to supply pharmaceutical products and medical commodities across multiple therapeutic domains to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. AmerisourceBergen Drug Corp's consistent performance on competitively awarded federal contracts demonstrates its capability to meet the diverse and substantial medical supply requirements of the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.7k | 7/21/25 |